PFF Stresses Differences Between COVID-19 and ILD Fibrosis Patterns

PFF Stresses Differences Between COVID-19 and ILD Fibrosis Patterns
4.1
(16)

COVID-19 has been reported to cause lung fibrosis in some people, but the type of fibrosis that develops is distinct from what generally occurs in those with interstitial lung disease (ILD), according to a press release issued by the Pulmonary Fibrosis Foundation (PFF).

COVID-19 (coronavirus disease 2019) is caused by a viral infection of the respiratory tract — the airway and lungs — that can cause severe disease in some people, particularly those who are older or have underlying conditions.

A subset of people with COVID-19 may develop pneumonia that progresses to acute respiratory distress syndrome (ARDS), a condition in which fluid builds up in the lungs, preventing oxygen from reaching the bloodstream. People who develop ARDS almost always require a ventilator to survive.

In some people who survive ARDS brought on by COVID-19, lung fibrosis (scarring) develops. However, according to the PFF, the type of fibrosis seen following infection is different from the type that characterizes ILDs.

ILD is an umbrella term for a group of conditions that are characterized by scarring in the lung, such as idiopathic pulmonary fibrosis. In ILDs, scarring is progressive — that is, it increases over time, gradually affecting the patient’s lung function.

Post-ARDS fibrosis is typically not progressive, meaning that scarring does not continue over time, although it can be severe and limiting in some cases.

In general, recovery from post-ARDS fibrosis takes about one year. And it is not uncommon for decreased lung function to persist after the recovery period, but again, and different from ILDs, such symptoms generally do not worsen over time.

According to the PFF, it is noteworthy that, since both ILDs and COVID-19-associated ARDS are sometimes characterized by lung fibrosis, the two disease processes might share some underlying biological mechanisms. This raises the possibility that therapies focused on treating ILDs also could have a potential application in the treatment of COVID-19. For now, however, this notion is hypothetical.

For more information about the COVID-19 pandemic and PF, visit our page.

The PFF recommends patients in the higher risk category, including those with pulmonary fibrosis, take measures to reduce the risk of being exposed to COVID-19. The foundation also has a list of several available resources for patients and caregivers regarding the pandemic.

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Total Posts: 110
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
×
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Latest Posts
  • Breathless Balad Challenge
  • IPF mortality decreases
  • AbbVie therapy agreement
  • patient satisfaction with treatments

How useful was this post?

Click on a star to rate it!

Average rating 4.1 / 5. Vote count: 16

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?